OTCPK:ARYC

Stock Analysis Report

Executive Summary

Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Arrayit has significant price volatility in the past 3 months.
  • Arrayit's last earnings update was 1366 days ago.
  • Arrayit is not covered by any analysts.

Similar Companies

Share Price & News

How has Arrayit's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-15.3%

OTCPK:ARYC

-0.5%

US Life Sciences

-1.0%

US Market


1 Year Return

-67.8%

OTCPK:ARYC

10.4%

US Life Sciences

-0.4%

US Market

ARYC underperformed the Life Sciences industry which returned 8.6% over the past year.

ARYC underperformed the Market in United States of America which returned -1.7% over the past year.


Share holder returns

ARYCIndustryMarket
7 Day-15.3%-0.5%-1.0%
30 Day-24.5%-4.0%-3.3%
90 Day-61.9%3.3%0.4%
1 Year-67.8%-67.8%10.6%10.4%1.8%-0.4%
3 Year3028.6%3028.6%70.1%68.7%39.4%30.4%
5 Year-86.3%-86.3%110.3%100.3%54.2%37.1%

Price Volatility Vs. Market

How volatile is Arrayit's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Arrayit undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Arrayit is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Arrayit has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Arrayit's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Arrayit regulatory filings here.
  • Explore potentially undervalued companies in the pharmaceuticals & biotech industry.

Future Growth

How is Arrayit expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.3%

Forecasted Life Sciences industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Arrayit has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Arrayit performed over the past 5 years?

12.9%

Historical Life Sciences annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Arrayit has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • Examine Arrayit's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Arrayit's filings and announcements here.
  • Explore strong past performing companies in the pharmaceuticals & biotech industry.

Financial Health

How is Arrayit's financial position?


In this section we usually analyse Arrayit's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Arrayit has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of ARYC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Arrayit's financial data was last updated here.
  • Explore more healthy companies in the pharmaceuticals & biotech industry.

Dividend

What is Arrayit's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Arrayit's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Arrayit's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Arrayit has not reported any payouts.

Unable to verify if Arrayit's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Arrayit has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Arrayit's salary, the management and board of directors tenure and is there insider trading?


CEO

Rene Schena (56yo)

11.5yrs

Tenure

US$78,750

Compensation

Ms. Rene A. Schena has been the Chairman of the Board and Chief Executive Officer of Arrayit Corporation (Formerly Integrated Media Holdings, Inc). since February 21, 2008. Ms. Schena serves as Chief Finan ...


CEO Compensation Analysis

Insufficient data for Rene to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.

Insufficient data for Rene to compare compensation growth.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$1,272,73909 Apr 19
Jason Nielsen
EntityIndividual
Shares30,816,345
Max PriceUS$0.057

Ownership Breakdown


Management Team

  • Rene Schena (56yo)

    Chairman

    • Tenure: 11.5yrs
    • Compensation: $78.75k
  • Bill Sklar (71yo)

    Financial Consultant

  • Todd Martinsky (54yo)

    Founder

    • Compensation: $84.38k
  • Mark Schena (56yo)

    President

    • Compensation: $5.63k
  • Paul Haje (63yo)

    Vice President of Sales & Marketing

    • Tenure: 11.6yrs
  • Ronald Cole

    Consultant


Board Members

  • Rene Schena (56yo)

    Chairman

    • Tenure: 11.5yrs
    • Compensation: $78.75k
  • Todd Martinsky (54yo)

    Founder

    • Tenure: 11.5yrs
    • Compensation: $84.38k
  • Mark Schena (56yo)

    President

    • Compensation: $5.63k

Company Information

Arrayit Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arrayit Corporation
  • Ticker: ARYC
  • Exchange: OTCPK
  • Founded:
  • Industry: life sciences tools and services
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$24.670m
  • Shares outstanding: 1.13b
  • Website: Click here

Number of Employees


Location

  • Arrayit Corporation
  • 927 Thompson Place
  • Sunnyvale
  • California
  • 94085
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARYCOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMay 2004

Biography

Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagno ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 00:18
End of Day Share Price2019/08/16 00:00
Earnings2015/09/30
Annual Earnings2014/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.